Comparison of Therapeutic Effect of Amantidine and Modafinil in Fatigue Related Multiple Sclerosis

Comparison of Therapeutic Effect of Amantidine and Modafinil in Fatigue Related Multiple Sclerosis Patients in Hamedan M.S Clinic (Neshat)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210511051267N1

Enrollment

150

Registered

2021-06-22

Start date

2021-07-21

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatigue related to multiple sclerosis. Multiple scle

Interventions

Intervention group:treatment groups.

Eligibility

Sex/Gender

All

Age

16 Years to 55 Years

Inclusion criteria

Inclusion criteria: Age(16-55) Fatigue related to MS Satisfaction for participation in the study

Exclusion criteria

Exclusion criteria: Narcolepsy Sleep apnea Major systemic disorder late use of Drowsiness and fatigue drugs Smoker Clinical history of thyroid, renal, cardiovascular disorders and diabetes and hepatitis Depression History of psychotic diseases

Design outcomes

Primary

Measure	Time frame
Fatigue rate based on FSS questionnaire(fatigue severity scale). Timepoint: At the beginning of the study and after three months of receiving the drugs. Method of measurement: In this study fatigue will be evaluated by standard fatigue severity scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Arab

Hamedan University of Medical Sciences

Drkhazaei@umsha.ac.ir+98 81 3838 0703

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026